Frank P. Esper

Frank P. Esper

Auto-generated profile, based on publicly available information

Frank P. Esper

Department of Pediatrics, Center for Pediatric Infectious Disease, Cleveland Clinic Children's , Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
FEFrank P Esper
Frank P Esper
TAThamali M Adhikari
Thamali M Adhikari
ZTZheng Jin Tu
Zheng Jin Tu
YCyu Cheng
yu Cheng
KEKim El-Haddad
Kim El-Haddad
BRBrian P Rubin
Brian P Rubin
Four severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants predominated in the United States since 2021. Understanding disease severity related to different SARS-CoV-2 variants remains limited. Viral genome analysis was performed on SARS-CoV-2 clinical isolates circulating March 2021 through March 2022 in Cleveland, Ohio. Major variants were correlated with disease severity and patient outcomes. In total 2779 patients identified with either Alpha (n = 1153), Gamma (n = 122), Delta (n = 808), or Omicron variants (n = 696) were selected for analysis. No difference in frequency of hospitalization, intensive care unit (ICU) admission, and death were found among Alpha, Gamma, and Delta variants. However, patients with Omicron infection were significantly less likely to be admitted to the hospital, require oxygen, or admission to the ICU (χ2 = 12.8, P < .001; χ2 = 21.6, P < .002; χ2 = 9.6, P = .01, respectively). In patients whose vaccination status was known, a substantial number had breakthrough infections with Delta or Omicron variants (218/808 [26.9%] and 513/696 [73.7%], respectively). In breakthrough infections, hospitalization rate was similar regardless of variant by multivariate analysis. No difference in disease severity was identified between Omicron subvariants BA.1 and BA.2. Disease severity associated with Alpha, Gamma, and Delta variants is comparable while Omicron infections are significantly less severe. Breakthrough disease is significantly more common in patients with Omicron infection.

1 April 2021 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
YMY. Mandelia
Y. Mandelia
GPG.W. Procop
G.W. Procop
SRS.S. Richter
S.S. Richter
SWS. Worley
S. Worley
WLW. Liu
W. Liu
FEF. Esper
F. Esper

1 October 2011 in Journal of Infection
Verified
Journal Article
Closed access
FEFrank P. Esper
Frank P. Esper
TSTimothy Spahlinger
Timothy Spahlinger
LZLan Zhou
Lan Zhou

9 May 2017 in Pathogens and Immunity
Verified
Journal Article
Open access
PDF file
DPDaniel L. Popkin
Daniel L. Popkin
SZSarah Zilka
Sarah Zilka
MDMatthew Dimaano
Matthew Dimaano
HFHisashi Fujioka
Hisashi Fujioka
CRCristina Rackley
Cristina Rackley
FEFrank Esper
Frank Esper
Background: There is a continued need for strategies to prevent influenza. While cetylpyridinium chloride (CPC), a broad-spectrum antimicrobial agent, has an extensive antimicrobial spectrum, its ability to affect respiratory viruses has not been studied in detail.Objectives: Here, we evaluate the ability of CPC to disrupt influenza viruses in vitro and in vivo.Methods: The virucidal activity of CPC was evaluated against susceptible and oseltamivir- resistant strains of influenza viruses. The effective virucidal concentration (EC) of CPC was determined using a hemagglutination assay and tissue culture infective dose assay. The effect of CPC on viral envelope morphology and ultrastructure was evaluated using transmission electron microscopy (TEM). The ability of influenza virus to develop resistance was evaluated after multiple passaging in sub-inhibitory concentrations of CPC. Finally, the efficacy of CPC in formulation to prevent and treat influenza infection was evaluated using the PR8 murine influenza model.Results: The virucidal effect of CPC occurred within 10 minutes, with mean EC50 and EC2log ranging between 5 to 20 µg/mL, for most strains of influenza tested regardless of type and resistance to oseltamivir. Examinations using TEM showed that CPC disrupted the integrity of the viral envelope and its morphology. Influenza viruses demonstrated no resistance to CPC despite prolonged exposure. Treated mice exhibited significantly increased survival and maintained body weight compared to untreated mice.Conclusions: The antimicrobial agent CPC possesses virucidal activity against susceptible and resistant strains of influenza virus by targeting and disrupting the viral envelope. Substantial virucidal activity is seen even at very low concentrations of CPC without development of resistance. Moreover, CPC in formulation reduces influenza-associated mortality and morbidity in vivo.Keywords: Cetylpyridinium Chloride, CPC, Influenza, Respiratory tract illness, respiratory virus, quaternary ammonium compound

1 December 2009 in Clinics In Laboratory Medicine
Verified
Journal Article
Closed access
BCBrian D.W. Chow
Brian D.W. Chow
FEFrank P. Esper
Frank P. Esper

14 January 2017 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
PMPranab Mukherjee
Pranab Mukherjee
FEFrank Esper
Frank Esper
KBKen Buchheit
Ken Buchheit
KAKaren Arters
Karen Arters
IAIna Adkins
Ina Adkins
RSRobert A. Salata
Robert A. Salata
Current prevention options for upper respiratory infections (URIs) are not optimal. We conducted a randomized, double-blinded, placebo-controlled pilot clinical trial to evaluate the safety and efficacy of ARMS-I™ (currently marketed as Halo™) in the prevention of URIs. ARMS-I is patented novel formulation for the prevention and treatment of influenza, comprising a broad-spectrum antimicrobial agent (cetylpyridinium chloride, CPC) and components (glycerin and xanthan gum) that form a barrier on the host mucosa, thus preventing viral contact and invasion. Healthy adults (18–45 years of age) were randomized into ARMS-I or placebo group (50 subjects each). The drug was sprayed intra-orally (3× daily) for 75 days. The primary objectives were to establish whether ARMS-I decreased the frequency, severity or duration of URIs. Secondary objectives were to evaluate safety, tolerability, rate of virus detection, acceptability and adherence; effect on URI-associated absenteeism and medical visits; and effect of prior influenza vaccination on study outcomes. Of the 94 individuals who completed the study (placebo: n = 44, ARMS-I: n = 50), six presented with confirmed URI (placebo: 4, ARMS-I: 2), representing a 55% relative reduction, albeit this was statistically not significant). Influenza, coronavirus or rhinovirus were detected in three participants; all in the placebo group. Moreover, frequency of post-treatment exit visits was reduced by 55% in ARMS-I compared to the placebo group (N = 4 and 2, respectively). Fever was reported only in the placebo group. ARMS-I significantly reduced the frequency and severity of cough and sore throat, and duration of cough (P ≤ .019 for all comparisons). ARMS-I was safe, well tolerated, had high acceptability and high adherence to medication use. Medical visits occurred only in the placebo group while absenteeism did not differ between the two arms. Prior influenza vaccination had no effect on study outcome. This randomized proof-of-concept clinical trial demonstrated that ARMS-I tended to provide protection against URIs in the enrolled study participants, while reducing severity and duration of cough and sore throat. A clinical trial with a larger number of study participants is warranted. ClinicalTrials.gov NCT02644135 (retrospectively registered).